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Abstract
Chronic viral hepatitis B remains a global public health concern. Currently, several drugs, such as tenofovir and
adefovir, are recommended for treatment of patients with chronic hepatitis B. tenofovir is a nucleoside analog with
selective activity against hepatitis b virus and has been shown to be more potent in vitro than adefovir. But the
results of trials comparing tenofovir and adefovir in the treatment of chronic hepatitis B were inconsistent. However,
there was no systematic review on the comparison of the efficacy of tenofovir and adefovir in the treatment of
chronic hepatitis B. To evaluate the comparison of the efficacy of tenofovir and adefovir in the treatment of chronic
hepatitis B we conducted a systematic review and meta-analysis of clinical trials. We searched PUBMED, Web of
Science, EMBASE, CNKI, VIP database, WANFANG database, the Cochrane Central Register of Controlled Trials and the
Cochrane Database of Systematic Review. Finally six studies were left for analysis which involved 910 patients in total,
of whom 576 were included in tenofovir groups and 334 were included in adefovir groups. At the end of 48-week
treatment, tenofovir was superior to adefovir at the HBV-DNA suppression in patients[RR = 2.59; 95%CI(1.01-6.67),
P = 0.05]. While there was no significant difference in the ALT normalization[RR = 1.15; 95%CI(0.96-1.37), P = 0.14],
HBeAg seroconversion[RR = 1.32; 95%CI(1.00-1.75), P = 0.05] and HBsAg loss rate[RR = 1.19; 95%CI(0.74-1.91),
P = 0.48]. More high-quality, well-designed, randomized controlled, multi-center trails are clearly needed to guide
evolving standards of care for chronic hepatitis B.
1. Introduction
Chronic hepatitis B virus (HBV) infection is a serious
global public health problem associated with cirrhosis,
liver failure and hepatocellular carcinoma (HCC) [1]. Of
the two billion people who have been infected, more
than 350 million have chronic hepatitis [2]. Several
major advances in the treatment of chronic hepatitis B
(CHB) have been made over the last several years. Cur-
rently, several drugs are recommended for treatment of
patients with CHB. These drugs can be divided into two
main groups based on their mechanism of action,
namely immunomodulatory drugs like alpha interferons
and antiviral drugs including lamivudine(LAM), telbivu-
dine(LdT), entecavir(ETV), adefovir(ADV), and tenofovir
(TDF) [3].
Adefovir dipivoxil, an acylic phosphonate, is a nucleo-
tide analog licensed for the treatment of HBV, which is
active against both negative and positive HBeAg [4,5].
Furthermore, it has been shown that ADV has an excel-
lent activity against wild-type as well as LAM-resistant
HBV strains [6,7]. However, ADV has low HBeAg sero-
conversion rate which was only 12%, less potency
toward HBV DNA suppression and a few drawbacks
including nephrotocicity for those who are at risk for
renal dysfunction [5]. Meanwhile at the licensed dose of
10 mg/day ADV is not a highly potent drug [8]. But the
advantage of ADV was the low rates of resistance. In
contrast to LAM, after 2 and 4 years of ADV treatment
only 3%, 18% of patients exhibit resistance respectively
[9]. In addition, both the ADV mutations, N236T and
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effective treatment option for HBV infection.
Tenofovir disoproxil fumarate (TDF), a new nucleo-
tide analogue licensed in 2008 for the treatment of
HBV infections in Europe and the United States [10],
also exhibits an efficacious activity against wild type
and LAM-resistant HBV, both in vitro[11] and in vivo
[12,13]. Randomized clinical trials have shown that
TDF is more potent than ADV in inhibiting HBV
replication in patients with chronic hepatitis [14]. The
same study showed the efficacy of TDF in patients
with a LAM-resistant virus and the absence of resistant
mutations after 48weeks of therapy. Besides, it has
shown antiviral efficacy against a broad spectrum of
viral infections, including human immunodeficiency
virus (HIV-1)[15].
Treatment of CHB with TDF versus ADV have been
reported in six independent studies [14,16-19], two of
them [16,18] on HIV-HBV coinfected patients and
another two of them on patients with LAM-resistant
[17,19]. These studies suggest a more promising result
using TDF than ADV. However, there are important dif-
ferences among these trials in study design, patient
populations and patient stat u s .T h ea i m so ft h i sr e v i e w
are to summarize their findings and assess the impact
on our management of the disease.
2. Methods
2.1. Search strategy
We searched the following databases until August 2010:
PUBMED (from 1990 to August 2010), Web of Science
(from 1990 to August 2010), EMBASE (from 1990 to
August 2010), CNKI (National Knowledge Infrastruc-
ture) (from 1990 to August 2010), VIP database (from
1990 to August 2010), WANFANG database (from 1990
to August 2010), the Cochrane Central Register of Con-
trolled Trials and the Cochrane Database of Systematic
Review. Of these databases, CNKI, WANFANG and VIP
databases provide literatures in Chinese. The search pro-
cess was designed to find initially all trials involving
terms: “Hepatitis B”, “tenofovir”, “adefovir"(and multiple
synonyms for each term). Reference lists from retrieved
documents were also searched. Computer searches were
supplemented with a manual search. Search results were
downloaded to a reference database and further
screened. Two authors (Shushan Zhao and Lanhua
Tang) independently screened all citations and abstracts
identified by the search strategy to identify potentially
eligible studies.
2.2. Types of studies
All relevant clinical trials will be included, irrespective of
language, or blinding. Observational studies will be
excluded except for their report on harms.
2.3. Types of participants
Male or female patients, of any age or ethnic origin,
who have CHB, defined as CHB virus infection with evi-
dence of hepatitis (alanine aminotransferase (ALT) ele-
vation of at least one and a half times the upper limit of
normal range) and of viral replication (detectable hepati-
tis B virus DNA by DNA hybridisation method or poly-
merase chain reaction (PCR)), will be included. Patients
with decompensated liver disease, hepatocellular carci-
noma, prior liver transplantation and concomitant renal
failure were excluded.
2.4. Types of interventions
The comparisons will include TDF versus ADV.
2.5. Types of outcome measures
Proportion of patients with HBV-DNA level under 1000
copies/ml, ALT normalization rate, HBeAg seroconver-
sion rate, HBsAg loss rate.
2.6. Data extraction
Data was extracted independently by both authors
(Shushan Zhao and Lanhua Tang) using a pre-designed
data extraction form and the information subsequently
was entered into Review Manager (RevMan 5.0). Infor-
mation was extracted on data source; eligibility; meth-
ods; participants (age range, exclusion criteria, sample
size, gender); interventions; and results. We resolved any
discrepancies between the extracted data by discussion,
and, if required, referral to the third author (Rongrong
Zhou). Where data were not clear or not presented by
the author in the publication, we attempted to contact
the trial author for further details. Data was extracted
on the methodological domains relevant to minimising
bias and random error in the analysis of trials by using
the Cochrane methods for assessing risk of bias and
GRADE methods [20]. Specifically, we assessed study
limitations by evaluating the method of randomisation,
allocation concealment, blinding, analysis by intention
to screen, free of selective reporting and so on. As per-
GRADE [20], we further assessed the quality of evidence
with regard to limitations in designs, inconsistency,
indirectness, imprecision, and other potential sources of
bias, such as publication and reporting bias. GRADE cri-
teria were then applied to downgrade the quality of evi-
dence when indicated on an outcome specific basis. The
quality of evidence for an individual outcome was ulti-
mately rated as high, moderate, low, or very low.
2.7. Quality assessment
Quality of the trials was assessed using the QUOROM
guidelines as well as using the Jadad scale. These
prompted downgrading of the overall quality of evidence
for all individual outcomes.
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Data analysis was carried out with the use of Review Man-
ager Software 5.0(Cochrane Collaboration, Oxford, United
Kingdom). For each eligible study, dichotomous data were
presented as relative risk (RR), which is the probability
that a member of an exposed group will develop a disease
relative to the probability that a member of an unexposed
group will develop that same disease, and continuous out-
comes were presented as weighted mean difference
(WMD), which is calculated as the difference between the
mean value in the treatment and control groups, both
with 95% confidence intervals (CI). Meta-analysis was per-
formed using fixed-effect or random-effect methods,
depending on the absence or presence of significant het-
erogeneity. Statistical heterogeneity between trials was
evaluated by the chi-square and I-square (I
2)t e s t s ,w i t h
significance set at P < 0.10. In the absence of statistically
significant heterogeneity, the fixed-effect method was used
to combine the results. When heterogeneity was con-
firmed (P < 0.10), the random-effect method was used.
Additionally, sensitivity analysis should be carried out if
low quality trials were included. The overall effect was
tested using z scores calculated by Fisher’sz ’ transforma-
tion, with significance set at P < 0.05.
3. Results
We searched relevant literatures, and finally a total of
1425 studies identified by the searches(PUBMED:161;
Web of Science:404; EMBASE:844; CNKI:3; VIP data-
base:1; WANFANG database:1; the Cochrane Central
Register of Controlled Trials and the Cochrane Data-
base of Systematic Review:11). By scanning titles and
abstracts, 722 redundant publications, review, and
meta-analysis were excluded. After referring to full
texts, 697 studies that did not satisfy the inclusion cri-
teria were removed from consideration. Six studies
[14,16-19] were left for analysis which involved 910
patients in total, of whom 576 were included in TDF
groups and 334 were included in ADV groups (Figure
1). According to treatment period, we divided the stu-
dies into two subgroups: LAM-resistance group and
HBV-HIV coinfected group. In addition, all studied
populations with comparable baseline characteristics
between TDF groups and ADV groups. Of the six
trials, all were published in English. The detailed infor-
mation of included trials was summarized in Table 1
and Table 2. With the exception of the study by van
Bommel et al [19]., which was not referred, all were
multicentred. However only four studies [14,17,18]
were multicentred involving sites in different countries.
T h el a s t e s to n e[ 1 4 ]w a sap h a s e□ trial comparing
T D Fw i t hA D V .O fa l lt r i a l s ,t h r e ew e r er a n d o md o u -
ble-blind trials. The treatment duration was more than
48 weeks and the end points were assessed at week 48.
All six trials contained patients of similar demo-
graphics in terms of age and sex distribution(Table 1).
T h em a j o r i t yo fp a t i e n t sw e r ei nt h e i rt h i r do rf o u r t h
decade of age and there was a male preponderance in
all studies. Two studies [17,19] included LAM-resis-
tance patients and two studies [16,18] included HIV-
HBV coinfetion patients. Different HBV-DNA assays
were used in these studies and thus the HBV-DNA
levels may not be directly comparable between studies.
In the trial by van Bommel et al [19], results showed
that TDF coped more effectively with the LAM-resistant
virus population than ADV at week 48 which were in
accordance with results from previous studies demon-
strating a HBV DNA decline at week 24. In this trial,
TDF is superior to ADV considering the fact that in all
TDF-treated patients HBV DNA became negative com-
pared with only approximately 44% of the ADV group.
And ALT levels normalized more rapidly in the TDF
group than in the ADV group. Interestingly, 5 of the
TDF-treated patients lost HBsAg. No major clinical side
effects were reported during treatment with either TDF
or ADV. In the trial by Hann et a[17]l, results showed
that after 6 months treatment, HBV DNA levels were
significantly reduced for the TDF group than for the
ADV group. After 12 months on therapy, mean HBV
DNA levels were reduced to 1.5 ± 1.0 log copies/ml for
the TDF group and 4.3 ± 2.2 log copies/ml for the ADV
group and the difference was significant which accorded
with the result of Bommel’s. However ALT normaliza-
tion and HBeAg loss at 12 months showed no signifi-
cant difference between two group.
In the study by Peters et al [18], either ADV or TDF
treatment resulted in clinically significant reductions in
serum HBV DNA levels in coinfected patients. TDF was
not inferior to ADV according to the HBV DNA sup-
pression. At week 48, 25% of subjects on ADV and 36%
of subjects on TDF normalized serum ALT, but these
numbers were not statistically significant either.
But in the study by Lacombe et al [16], the HBV-DNA
decay was more significant in patients treated with TDF
than with ADV, even after adjustment for baseline HBV
viral load. And undetectability (HBV-DNA < 200
copies/mL) was reached by 66% and 28% patients trea-
ted with TDF and ADV, respectively (p = 0.04). How-
ever similar rates of HBeAg seroconversion and HBsAg
loss were found between two groups.
The study by Marcellin et al [14] include two trials:
study 102 (HBeAg-negative patients) and study 103
(HBeAg-positive patients). In both studies, a significantly
greater proportion of patients who received TDF than
patients who received ADV reached the HBV DNA level
of less than 400 copies/ml. Among the HBeAg-negative
patients, 93% of all the patients who received TDF had a
plasma HBV DNA level of less than 400 copies/ml by
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had(p < 0.01). Among HBeAg-positive patients, 76% of
patients who received TDF had an HBV DNA level of
less than 400 copies/ml at week 48 while 13 of patients
who received ADV had(p < 0.01). In Study 102, similar
proportions of patients in the two treatment groups had
normalized alanine aminotransferase levels at week 48,
whereas in Study 103, a significantly greater proportion
of patients in the TDF group had normalized alanine
aminotransferase levels.
Despite the differences in types of patient population,
study design and patients’ status, the six trials appear to
demonstrate that TDF is superior to ADV in HBV-DNA
decay. However there are different results on ALT
normalization. So a meta-analysis is necessary to com-
bine the results of those six studies.
Only three trials [14,19] demonstrated the HBV-DNA
level decreases below 400 copies/ml. According to chi-
squared statistic and I square(I
2), heterogeneity was
assessed and had significant differences[Tau
2 = 0.65;
Chi
2 = 35.89, df = 2 (P < 0.00001); I
2 = 94%]. A sum-
mary estimate of the relative risk of TDF versus ADV
by use of a random-effects approach. The results of the
three trials showed HBV-DNA level below 400 copies/
ml in the TDF group was 87.2%, compared to 42.5% in
t h eA D Vg r o u pa tw e e k4 8 .A n dt h ee f f i c a c yo fH B V -
DNA suppression rates in TDF group was higher than
ADV group[RR = 2.59, 95%CI(1.01-6.67), P = 0.05]
Figure 1 Flow diagram of the studies identified.
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the low quality trial [19] was removed[RR = 2.58, 95%
CI(0.56-14.56), P = 0.21]. The quality of evidence for
this effect was judged low (Table 3). Just one study [19]
demonstrated the HBV-DNA level decreases below 400
copies/ml in LAM-resistance subgroup. The result
showed the HBV-DNA suppression rates in TDF group
was higher than ADV group[RR = 2.20, 95%CI(1.34-
3.64), P = 0.002]. Two studies [16,18] demonstrated the
HBV-DNA level decreased below 200 copies/ml in
HBV-HIV coinfected subgroup. The results showed
HBV-DNA level below 200 copies/ml for in the TDF
group was 50.6%, compared to 18.5% in the ADV group
at week 48. And the HBV-DNA suppression rates in
TDF group was higher than ADV group[RR = 2.38, 95%
CI(1.34-4.24), P = 0.003](Figure 3). The quality of evi-
dence for this effect was judged moderate.
Five studies [14,17-19] demonstrated the ALT normali-
zation rate in this subgroup. According to chi-squared
statistic and I square (I
2), a random-effects approach was
used to summary estimate the relative risk of TDF versus
ADV. The results of the five trials showed normalization
rates for ALT in the TDF group as 72.1%, compared to
63.3% in the ADV group at week 48. And the biochem-
ical response rates in TDF group was similar with the
ADV group [RR = 1.15, 95%CI(0.96-1.37), P = 0.14](Fig-
ure 4). The quality of evidence for this effect was judged
low. The result was unchanged when low quality trials
[17,19] were removed[RR = 1.08, 95%CI(0.87-1.33), P =
0.49]. The quality of evidence for this effect was judged
moderate. In the LAM-resistance subgroup, a fix-effects
approach was used to summary estimate the relative risk
of TDF versus ADV and the efficacy of TDF versus ADV
on ALT normalization rates is also similar[RR = 1.32,
95%CI(1.00-1.74), P = 0.05] (Figure 5). The quality of evi-
dence for this effect was judged low.
Three trials [14,16,17] demonstrated the HBeAg sero-
conversion rate in this subgroup. According to chi-
squared statistic and I square(I
2), heterogeneity was
assessed and not found to be a concern[Chi
2 = 0.00, df = 1
Table 1 Summary of study design of the six trials
Study Marcellin Study 102
[14]
Marcellin Study 103
[14]
Lacombe [16] Hann [17] Peters [18] van Bommel [19]
Study
location
Worldwide Worldwide French multi-centre Asian-Americans Worldwide N/A
Study
design
randomized,double-
blind
randomized,double-
blind
non-randomized,
open label
quasi-randomized,
open-label
prospective
randomized, double-
blind
Nonrandmoized,
open-label
Grade 5 5 2 3 5 2
Treatment
options
Tenofovir 300 mg/d
vs Adefovir 10 mg/d
Tenofovir 300 mg/d
vs Adefovir 10 mg/d
Tenofovir 300 mg/d
vs Adefovir 10 mg/d
Tenofovir 300 mg/d
vs Adefovir 10 mg/d
Tenofovir 300 mg/d
vs Adefovir 10 mg/d
Tenofovir 300 mg/d
vs Adefovir 10 mg/d
Male 193(77%) vs. 97(78%) 119(68%) vs. 64(71%) 54(96.4%) vs. 28
(26.6%)
37(85%) vs. 49(76%) 24 (89%) vs. 24
(96%)
32(91.4%) vs. 14
(77.8%)
Mean age,
years
44 ± 10.6 vs.
43 ± 10
34 ± 11 vs. 34 ± 12 42.3 vs. 41.5 49 vs. 45 40 vs. 47 47 ± 2 vs. 45 ± 3.7
HBeAg-
positive
(%)
0:0 1:1 50(89.3%) vs. 25
(86.2%)
33(75%) vs. 55(84%) 23 (85%) vs. 20
(80%)
31(89%) vs16( 89%)
Treatment
(weeks)
48 weeks 48 weeks 48 weeks 48 weeks 48 weeks 72 to 130 weeks vs.
60 to 80 weeks
Follow-up
(weeks)
N/A N/A N/A 48 weeks 91 weeks vs. 81
weeks
N/A
Status N/A N/A Coinfect HIV lamivudine-resistant Coinfect HIV lamivudine-resistant
Table 2 Methodological quality of randomised controlled trials
Study Adequate sequence
generation
Allocation
concealment
Blinding Incomplete outcome data
addressed
Free of selective
reporting
Free of other
bias
Marcellin Study
102 [14]
yes yes yes yes yes yes
Marcellin Study
103 [14]
yes yes yes yes yes yes
Lacombe [16] no no no yes yes unclear
Hann [17] unclear unclear unclear yes unclear unclear
Peters [18] yes yes yes yes yes yes
van Bommel [19] no no no yes yes unclear
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2 = 0%]. The results of the three studies
showed the HBeAg seroconversion rate for the TDF group
was 18.6% while the ADV group response rate was 14.0%.
The difference of HBeAg seroconversion rates at week 48
between the two group was similar[RR = 1.19, 95%CI
(0.74-1.91), P = 0.48] (Figure 6). The quality of evidence
for this effect was judged low. Two trials demonstrated
the HBsAg loss rate in this subgroup and the difference of
HBsAg loss rate between the two group was similar[RR =
5.74, 95%CI (0.32-102.59), P = 0.23]. The quality of evi-
dence for this effect was judged high (Table 3).
Toleraility and safety of tenofovir and adefovir
The most frequently reported adverse events in TDF-
treatmented patients, which included headache, naso-
pharyngitis, fatigue, diarrhea, upper abdominal pain, and
so on, were those normally associated with ADV except
nausea. In Marcellin’st r i a l ,i t ’sr e p o r tt h a tn a u s e aw a s
the only adverse event that consistently occurred more
frequently in the group of patients who received TDF
than in the group of patients who received ADV.
Among the cases of nausea that were considered to be
related to TDF, nausea was mild except for one case of
grade 2 (moderate) nausea. Despite presence of these
adverse effects, rate of withdrawal from both treatments
was rare in all studies. In both studies, similar propor-
tions of patients in the two treatment groups had a ser-
ious adverse event, and few events were considered to
be related to the study drug. The frequency of alanine
aminotransferase flares during treatment was also simi-
lar in the two groups. These was no death associated
with the treatment, or liver decompensation.
4. Dicussion
There have been several meta-analysis comparing drugs
in the treatment of chronic hepatitis B [21,22], but no
comparison of the efficacy of TDF and ADV have been
performed. So we conducted this meta-analysis to com-
pare antiviral efficacy of TDF and ADV in the treatment
of CHB; despite variations in study design among the
Table 3 Methodological quality of randomised controlled trials
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)†
Assumed risk (per
1000)
Corresponding risk
(per 1000)
Adefovir Tenofovir
HBV-DNA suppression 425 1000(429 to 1000) RR 2.59 (1.01 to
6.67)
694(3 studies) low⊕⊕▯▯
HBV-HIV coinfected
subgroup
185 440(248 to 784) RR 2.38 (1.34 to
4.24)
137(2 studies) moderate⊕⊕⊕▯
ALT normalization 634 729(609 to 869) RR 1.15 (0.96 to
1.37)
768(5 studies) low⊕⊕▯▯
lamivudine-resistance
subgroup
554 731(554 to 964) RR 1.32 (1.00 to
1.74)
132(2 studies) low⊕⊕▯▯
HBeAg seroconversion 140 167(104 to 267) RR 1.19 (0.74 to
1.91)
387(3 studies) low⊕⊕▯▯
HBsAg loss 0 0 RR 5.74 (0.32 to
102.59)
615(2 studies) high⊕⊕⊕⊕
*The corresponding risk (and its 95% CI) is based on the assumed risk in the entecavir group and the relative effect of the lamivudine (and its 95% CI).
†High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality:
Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We
are very uncertain about the estimate.
Figure 2 Effect of TDF vs. ADV on HBV-DNA suppression at week 48.
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showed that at the end of 12 months treatment, TDF
was better than ADV at the HBV-DNA suppression,
while there was no significant difference in the ALT
normalization, HBeAg seroconversion and HBsAg loss
rate. Meanwhile there are similar results in the ALT
normalization in the LAM-resistance and suppression of
viral replication in HIV-HBV coinfected subgroup. The
inter-heterogeneity was not statistically significant(P >
0.1). There were on changes about effect when a ran-
dom-effect model was used. Interestingly, the result of
HBV-DNA suppression was changed when the low qual-
ity [19] trial was removed[RR = 2.58, 95%CI(0.56-14.56)
P = 0.21]. But the confidence intervals became wider, so
we think that the findings should be reinterpreted when
more researches done. Adverse events related to TDF
and ADV did occur but none appeared to be lifethrea-
tening. So this meta-analysis showed that TDF was a
more potent therapy for the treatment of chronic HBV
infection than ADV. However, TDF was just effective in
suppressing HBV-DNA levels. Considering its favorable
long-term safety record in patients with HIV-1 infection,
TDF should be used for the treatment of chronic HBV
infection.
While the results of this meta-analysis were promising,
there are questions that remain unresolved. Peters and
Lacombe’s study [16,18] have been the only two trials to
compare efficacy of HBV-DNA suppression in HIV
coinfected patients, however those two trials have a
small sample size and different study location. van Bom-
mel and Hann’s trials [17,19] have been the only two
studies to compare efficacy of ALT normalization in
LAM-resistance patients, however both trials have a low
Jadad score and small sample size. Although this meta-
analysis showed TDF was superior to ADV on HBV
DNA suppression in HIV-coinfected subgroup, these two
trials had different Jadad score. And when the low quality
[16] trials was removed, the conclusion was changed [RR
= 2.31, 95%CI (0.49-10.87), P = 0.29]. So is TDF really
more efficacious than ADV on HBV-DNA suppression in
the HIV coinfected patients and similar with ADV on
ALT normalization in the LAM-resistance subgroup?
More solid data is needed in the future. Another unre-
solved issue is related to the HBeAg seroconversion and
HBsAg loss to TDF and ADV therapy in HBV infection.
The studies so far have provided no evidence of efficacy
in terms of HBeAg seroconversion and HBsAg loss.
Meanwhile, follow-up of patients will be needed to detect
delayed viral suppression or relapse. More importantly,
the clinical outcomes in terms of liver-related complica-
tions, mortality and hepatocellular carcinoma should be
assessed [23]. Besides there are different outcomes
on HBV-DNA level in the six trials and it made difficult
to extract data, so it is necessary to make a basic
uniform standards for all trails outcome. After all, more
high-quality, well-designed, randomized controlled,
Figure 4 Effect of TDF vs. ADV on ALT normalization at week 48.
Figure 3 Effect of TDF vs. ADV on HBV-DNA suppression in HBV-HIV subgroup at week 48.
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resistance or HIV coinfected patients would be needed.
There are several methodological limitations in the
trials that have been reviewed warrant some discussion.
First, only three studies were double-blinded. Although
the intervention is easy to blind, there are several trials
didn’t use. However, it is unlikely that the lack of blind-
ing could affect the outcomes assessed [24]. Second, as
LAM-resistance and HIV-HBV coinfected patients were
studied in two of the six included trials respectively, it is
likely that our meta-analysis included different patient
groups. So the multiple subgroup analyses are per-
formed to detect the efficacy of TDF and ADV in the
treatment of CHB. Third, three trials didn’t describe the
method used to generate the allocation sequence.
Despite these potential sources of bias, randomization
was adequate in the six trials as shown by the baseline
equivalency of treatment groups. Finally, the different
HBV DNA assays used in the different trials may also
have caused additional variability in the sensitivity of
HBV DNA detection and thus in the estimate of
efficacy.
Another potentially important limitation of meta-
analysis is publication bias, the fact that not all research
is published. Compared to positive studies, negative stu-
dies may be less likely to be published and more likely
to take longer to be published, which can affect the
validity of meta-analysis [25]. One commonly used
method to detect publication bias is the ‘funnel plot,’
which is a scatter plot that displays the relationship
between the weight of the study and the observed effect.
In principle, larger studies should display less variability
of the treatment effects. Asymmetric appearance, espe-
cially due to the absence of smaller negative studies, can
suggest unpublished data. However, neither Egger’st e s t
nor funnel plots showed evidence for publication bias.
In summary, the results of this meta-analysis indicate
that a twelve-month TDF treatment was superior to
ADV in inhibiting HBV replication in CHB patients. But
there was no significant difference in the ALT normali-
zation, HBeAg seroconversion and HBsAg loss rate.
More high-quality, well-designed, randomized con-
trolled, multi-center trails that are adequately powered
are clearly needed to guide evolving standards of care
for CHB.
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